HBK Sorce Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
HBK Sorce Advisory's VRTX Position: Q1 2026 in Review
HBK Sorce Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 5.6% in Q1 2026, buying an estimated $21.9K and bringing the position to 882 shares worth $379K. The position accounts for 0.01% of the portfolio, ranked #431.
HBK Sorce Advisory first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $399K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- HBK Sorce Advisory held 882 shares of Vertex Pharmaceuticals worth $379K as of Q1 2026.
- HBK Sorce Advisory bought 47 Vertex Pharmaceuticals shares in Q1 2026, an estimated $21.9K.
- Vertex Pharmaceuticals made up 0.01% of HBK Sorce Advisory's portfolio in Q1 2026, its #431 holding.
- HBK Sorce Advisory first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
- HBK Sorce Advisory's Vertex Pharmaceuticals position peaked at $399K in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on HBK Sorce Advisory's 13F filing for Q1 2026, filed 11 May 2026.